Rocky Mountain Leukemia, Lymphoma & Myeloma Summit

Rocky Mountain Leukemia, Lymphoma & Myeloma Summit - Precision. Progress. Practice. is organized by Binaytara Foundation (BTF) and will be held from Sep 18 - 19, 2026 at Hyatt Regency Salt Lake City, Salt Lake City, Utah, United States of America.

Description:
The Rocky Mountain Leukemia, Lymphoma & Myeloma Summit is a CME-accredited educational conference convening leading hematologic oncology experts and multidisciplinary care teams in the heart of the Mountain West. Designed to serve oncology professionals across Utah, Idaho, Nevada, Colorado, Wyoming, and Montana, the Summit addresses the significant and rapidly evolving landscape of blood cancer care bringing world-class hematologic oncology education to a region where access to subspecialty expertise has historically been limited.

The program delivers in-depth analysis of the latest clinical trial data, FDA approvals, and practice-changing advances across leukemia, lymphoma, and myeloma spanning novel targeted therapies, next-generation immunotherapies, CAR-T and bispecific antibody platforms, and the expanding role of precision medicine in risk stratification and treatment selection. Faculty will contextualize emerging evidence within real-world practice, address the most pressing clinical controversies, and provide actionable frameworks for applying cutting-edge data to patient care in both academic and community settings. This activity is designed to improve the knowledge and clinical competence of hematology and oncology professionals to critically evaluate and apply the latest advances in leukemia, lymphoma, and myeloma translating emerging evidence in precision medicine, novel therapeutics, and cellular therapy into optimized, individualized patient care across the Mountain West region.

Learning Objectives:
At the conclusion of this activity, participants will be able to:

1. Evaluate the clinical significance of emerging cytogenetic, molecular, and genomic markers in leukemia, lymphoma, and myeloma, and apply evidence-based testing strategies to guide individualized risk stratification and treatment planning.
2. Analyze data from recently reported and ongoing clinical trials assessing novel targeted therapies, next-generation immunotherapies, bispecific antibodies, and CAR-T cell therapies across hematologic malignancies, including newly diagnosed and relapsed/refractory settings.
3. Integrate current evidence-based guidelines and expert consensus into treatment decision-making for patients with leukemia, lymphoma, and myeloma, with emphasis on sequencing therapies and adapting strategies at disease progression.
4. Identify strategies to recognize, prevent, and manage treatment-related toxicities associated with novel hematologic therapies, including cytokine release syndrome (CRS), immune effector cell-associated neurotoxicity syndrome (ICANS), and on-target off-tumor effects of targeted agents.
5. Apply advances in minimal residual disease (MRD) assessment, measurable residual disease-guided therapy, and precision medicine to optimize long-term outcomes, inform treatment discontinuation decisions, and support survivorship planning for patients with hematologic malignancies.